On May 14, 2026 CREATE Medicines, Inc. ("CREATE"), a clinical-stage biotechnology company pioneering in vivo immune programming, reported the closing of its $122 million Series B funding round, co-led by existing investors Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners, with participation from Alexandria Venture Investments and other current members of CREATE’s investor syndicate.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The funding will support advancement of CREATE’s clinical pipeline across autoimmune disease and oncology. To date, CREATE has dosed more than 50 patients across its in vivo CAR clinical programs — the largest clinical dataset in the field — generating the translational foundation that informs development across both autoimmune disease and oncology. The company’s proprietary mRNA-LNP platform programs immune cells directly inside the body, enabling a rapid, iterative product engine designed to compress concept-to-clinic timelines.

In autoimmune, CREATE’s lead program CRT-402, a next generation CD19 targeted in vivo CAR-T therapy, has demonstrated deep and durable B cell depletion in non-human primates, with the potential to enable immune reset through the flexibility of repeat dosing. The company is also advancing a dual CAR CD19 x BCMA directed therapy designed to broaden therapeutic reach across refractory autoimmune indications.
In oncology, CREATE continues to advance therapies focused on areas of high unmet need. Early clinical data from the company’s MT-303 program in frontline hepatocellular carcinoma has demonstrated an extremely compelling response profile.
Collectively, these programs exemplify CREATE’s iterative platform that integrates clinically validated CAR architectures, optimized RNA design, and targeted delivery technologies with deep expertise across clinical development, translational medicine, manufacturing, and regulatory execution.
"CREATE was built as an iterative immune programming platform in which each clinical study informs and strengthens the next, and it is that work that has revealed the breadth of what in vivo immune programming can address," said Daniel Getts, PhD, Chief Executive Officer of CREATE Medicines. "Our autoimmune and oncology pipeline represents the convergence of years of platform development, clinical execution, and translational learning. We believe our ability to engineer multiple immune cell populations directly in vivo has the potential to fundamentally reshape treatment paradigms across autoimmune disease and oncology, and we look forward to this next chapter of innovation and growth."

In conjunction with the Series B Round, Ron Philip, a veteran biopharma leader, has joined CREATE as Executive Chairman. Brian Cuneo, Senior Partner at ARCH Venture Partners, and Tom Thomas, PhD of Newpath Partners, have joined the company’s Board of Directors.

"I’m excited to join CREATE at this pivotal moment in the company’s evolution," said Ron Philip. "CREATE has established meaningful in vivo clinical proof points and built a differentiated immune programming platform with the potential to redefine how engineered immune therapies are developed and delivered. The opportunity to translate these capabilities into transformative medicines across autoimmune disease and oncology is exceptionally compelling."

"I co-founded this company because the science was ahead of the field. More than fifty patients later, it still is. Most in vivo cell therapy companies will struggle to translate science into scalable manufacturing. CREATE owns its manufacturing infrastructure. I am backing CREATE because it can become the next great standalone pharmaceutical company," said Tom Cahill, MD, PhD, Founder and Managing Partner of Newpath Partners.

"CREATE is building one of the most differentiated in vivo immune engineering platforms in the field," said Brian Cuneo. "We believe the company’s clinical experience, repeat dose strategy, and broad immune programming capabilities position it to play an important role in the future of autoimmune disease and oncology."

(Press release, Create Medicines, MAY 14, 2026, View Source [SID1234665733])

On May 14, 2026 Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet medical need, reported that it will host a virtual key opinion leader event focused on the evolving clinical and translational data supporting the development of (Z)-endoxifen, the Company’s investigational selective estrogen receptor modulator/degrader, or SERM/D, as a potential next-generation endocrine therapy backbone across multiple estrogen receptor ("ER") -positive breast cancer settings.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will feature internationally recognized surgical oncologist and breast cancer expert Dr. Laura Esserman. Dr. Esserman serves as Director of the University of California San Francisco Breast Care Center and is the founder and principal investigator of the I-SPY Trials, an innovative platform designed to accelerate the development of personalized breast cancer therapies.

"Dr. Esserman has been at the forefront of innovation in breast cancer clinical research, adaptive trial design, and precision oncology for decades," said Dr. Steven Quay, M.D., Ph.D., Chairman and Chief Executive Officer of Atossa Therapeutics. "We believe (Z)-endoxifen has the potential to become more than a single-indication therapy; it may serve as an endocrine therapy platform across multiple ER-positive breast cancer settings. Dr. Esserman’s leadership in translational breast cancer research makes her an ideal expert to discuss the emerging clinical and biomarker data supporting this opportunity."

The discussion is expected to address several topics of interest to clinicians, investors, and potential strategic partners, including:

Recent data from the I-SPY2 Endocrine Optimization Pilot study evaluating (Z)-endoxifen as monotherapy in newly diagnosed ER-positive breast cancer patients
Translational biomarker data, including Ki-67 reduction, MRI functional tumor volume changes, and circulating tumor DNA dynamics
Data supporting (Z)-endoxifen activity across clinically relevant ESR1 mutations, including Y537N, Y537S, and D538G
The rationale for (Z)-endoxifen as a potential next-generation endocrine therapy backbone
Combination strategies, including CDK4/6 inhibitor combinations
Development opportunities in premenopausal breast cancer and endocrine therapy optimization
Event Details

Date: Tuesday, May 19, 2026
Time: 1:00 to 2:00 p.m. PT
Moderator: Michael King, Managing Director at Rodman & Renshaw
Registration: View Source

Attendees may submit questions to [email protected] up to 24 hours prior to the event.

A replay of the webcast will be available on the Company’s "Investors" portion of its website for at least 60 days following the live event.

About (Z)-Endoxifen

(Z)-endoxifen is a potent Selective Estrogen Receptor Modulator/Degrader, or SERM/D, with demonstrated activity across multiple mechanisms of action. Atossa is evaluating its potential applications in oncology and rare diseases. The Company’s proprietary oral formulation has shown a favorable safety profile and pharmacology distinct from tamoxifen, including ER-targeted effects and PKC inhibition. Atossa’s (Z)-endoxifen is not approved for any indication.

(Press release, Atossa Therapeutics, MAY 14, 2026, View Source [SID1234665732])

On May 14, 2026 Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, reported the pricing of senior unsecured notes in an aggregate principal amount of $3 billion, in an underwritten, registered public offering, consisting of $500 million of 4.250% senior notes maturing in 2028, $1 billion of 4.400% senior notes maturing in 2029, $1 billion of 4.600% senior notes maturing in 2031 and $500 million of 4.900% senior notes maturing in 2034. The offering is expected to close on May 20, 2026, subject to customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Gilead intends to use the net proceeds from this offering for general corporate purposes, which may include funding for acquisitions, investments, strategic transactions or other business opportunities.

Barclays Capital Inc., BofA Securities, Inc. and Citigroup Global Markets Inc. are acting as lead joint book-running managers in the offering. The offering of the securities is being made only by means of a prospectus supplement and the accompanying base prospectus, which is filed as part of Gilead’s effective shelf registration statement on Form S-3 (File No. 333-273745), copies of which may be obtained from:

Barclays Capital Inc.

c/o Broadridge Financial Solutions,

1155 Long Island Avenue

Edgewood, NY 11717

(888) 603-5847

Email: [email protected]

BofA Securities, Inc.

NC1-022-02-25

201 North Tryon Street

Charlotte, NC 28255

(800) 294-1322

Email: [email protected]

Citigroup Global Markets Inc.

c/o Broadridge Financial Solutions,

1155 Long Island Avenue

Edgewood, NY 11717

(800) 831-9146

Email: [email protected]

An electronic copy of the prospectus supplement and the accompanying base prospectus and other documents Gilead has filed with the U.S. Securities and Exchange Commission (the "SEC") may also be obtained at no charge at the SEC’s website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

(Press release, Gilead Sciences, MAY 14, 2026, View Source [SID1234665731])

On May 14, 2026 EDAP TMS S.A. (Nasdaq: EDAP) reported that it has entered into a letter of intent with Telix Pharmaceuticals Limited ("Telix") to explore joint clinical research activities and physician education focused on the combination of EDAP’s Focal One Robotic HIFU and Telix’s PSMA PET imaging products in the management of prostate cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The initial area of investigational focus is expected to study the combination of PSMA PET diagnostic imaging scans within the Focal One HIFU treatment workflow to optimize treatment planning, deliver a precise, image-guided focal therapy treatment, and monitor responses after treatment and during subsequent patient follow-up. This collaboration will be investigated in both the primary treatment setting as well as the salvage treatment setting after radiation therapy.

Based on early clinical experience integrating PSMA PET with Focal One HIFU and with the recently published prospective HIFI-2 study showing positive patient outcomes using Focal One to treat patients with recurrence after radiation therapy, this combination with Telix holds the promise to further improve patient outcomes.

"We are uniquely designed to enable the integration of PSMA PET imaging with Focal One’s real-time ultrasound and fully robotic energy delivery to optimize treatment efficacy while minimizing side effects," said Ryan Rhodes, EDAP Chief Executive Officer. "As the market leader in robotic focal therapy, with a growing global installed base, this collaboration will accelerate the development and standardization of treatment strategies to further personalize focal therapy treatments using Telix’s PSMA PET imaging agents and Focal One Robotic HIFU."

"Precision medicine requires precision treatment strategies," said Kevin Richardson, Telix Precision Medicine Chief Executive Officer. "As disruptive technologies continue to transform prostate cancer care, we believe PSMA PET imaging has the potential to play an important role in helping clinicians better inform treatment decisions across a range of minimally invasive and image-guided treatment approaches. We are excited to explore a collaboration with Focal One that may further advance personalized care for patients."

The parties may also explore clinician educational programs such as webinars, symposia, and training initiatives and clinical studies involving mutual customers managing patients with Telix PSMA PET imaging products and Focal One Robotic HIFU.

The parties may enter into more definitive agreements in the future. There can be no assurance that any specific initiatives or programs will result from this initial collaboration, and the letter of intent imposes no obligation on either party to enter into any such agreement. The parties have not made any financial commitments under the letter of intent, and the collaboration is not expected to have a material impact on EDAP’s financial results.

(Press release, EDAP TMS, MAY 14, 2026, View Source [SID1234665730])

On May 14, 2026 NuCana plc (NASDAQ: NCNA) ("NuCana" or the "Company") reported financial results for the first quarter ended March 31, 2026 and provided an update on its clinical development program with its two lead anti-cancer medicines.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to report continued progress in the first quarter of 2026 as NUC-7738 advances towards important clinical and regulatory milestones," said Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer. "During the quarter, we continued to advance enrollment for our Phase 2 NuTide:701 expansion study evaluating NUC-7738 in combination with Keytruda (pembrolizumab) in patients with PD-1 inhibitor-resistant metastatic melanoma. The clinical activity and favorable safety profile previously reported, including confirmed objective responses and prolonged disease control, continue to support the therapeutic potential of NUC-7738 in this patient population, and we look forward to reporting final data from this study, which is expected later in 2026."

"We are also delighted to announce that the U.S. Food and Drug Administration (the "FDA") cleared our Investigational New Drug application ("IND") for NUC-7738 in April 2026. This important milestone enables clinical investigation of NUC-7738 in the United States and we expect our initial focus will be in patients with melanoma. We look forward to advancing our dialogue with the FDA to determine the optimal pathway toward a potential registrational strategy for NUC-7738 in melanoma."

Mr. Griffith continued, "Beyond our near-term, anticipated milestones in melanoma, we are actively exploring opportunities to broaden the clinical utility of NUC-7738 through additional indications and combination strategies. The mechanism of action of NUC-7738, disrupting RNA polyadenylation and targeting multiple aspects of the tumor microenvironment, positions it as a potentially versatile agent across a range of tumor types, and we are encouraged by the scientific rationale supporting its evaluation in new settings. We believe these efforts have the potential to significantly expand the long-term value of NUC-7738 for patients and for NuCana."

Mr. Griffith concluded, "Our strong balance sheet, with cash resources expected to fund operations into 2029, provides us with the financial flexibility to execute on our strategic priorities and advance our pipeline. We look forward to achieving important anticipated milestones throughout the remainder of 2026."

2026 Anticipated Milestones

NUC-7738
Complete patient recruitment in the Phase 2 expansion study (NuTide:701) evaluating NUC-7738 in combination with pembrolizumab in patients with PD-1 inhibitor-resistant melanoma;
Announce final data from the Phase 2 expansion study (NuTide:701) of NUC-7738 in combination with pembrolizumab in patients with PD-1 inhibitor-resistant melanoma;
Obtain regulatory guidance from the FDA regarding a potential registrational strategy for NUC-7738 in melanoma; and
Advance evaluation of additional indications and combination strategies.
NUC-3373
Complete evaluation of optimal combinations and indications to inform potential future clinical studies of NUC-3373.

First Quarter 2026 Financial Highlights and Cash Position

As at March 31, 2026, NuCana had cash and cash equivalents of £21.5 million compared to £24.3 million at December 31, 2025. NuCana anticipates its cash and cash equivalents at March 31, 2026 will be sufficient to fund its planned operations into 2029.

NuCana reported a net loss of £3.9 million for the quarter ended March 31, 2026, as compared to a net loss of £2.5 million for the quarter ended March 31, 2025. The net loss for the quarter ended March 31, 2026 included non-cash share-based payment expenses of £1.9 million (2025: £0.3 million).

Basic and diluted loss per ordinary share was £0.00 for the quarter ended March 31, 2026, as compared to a loss per ordinary share of £0.02 for the comparable quarter ended March 31, 2025.

(Press release, Nucana, MAY 14, 2026, View Source [SID1234665728])